Jaguar health announces issuance of u.s. patent 11,389,424, a methods and compositions patent for treating chemotherapy-induced diarrhea

New patent bolsters intellectual property protection for the company's core target indication for crofelemer crofelemer is the subject of the company's ontarget study, an ongoing pivotal phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy san francisco, ca / accesswire / august 9, 2022 / jaguar health, inc. (nasdaq:jagx) today announced that the united states patent and trademark office on july 19, 2022 issued a new u.s. patent to napo pharmaceuticals (napo), the company's wholly owned subsidiary, for methods for treating diarrhea, as well as the pain, abdominal discomfort and other symptoms associated with diarrhea, in patients with an inhibitor of chloride-ion transport such as napo's crofelemer drug product. "we are very pleased that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core target indication of cancer therapy-related diarrhea (ctd)," said lisa conte, jaguar's founder, president, and ceo.
JAGX Ratings Summary
JAGX Quant Ranking